Sandbox Turky2: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{| border="5" cellpadding="5" | {| border="5" cellpadding="5" | ||
|+ '''GI infection''' | |+ '''GI infection''' | ||
! Pathogen !! Immunocompetent patients !! Immunocompromised patients | ! Pathogen !! style="background:#CCFFCC;"|Immunocompetent patients !! style="background:pink"|Immunocompromised patients | ||
|- align="center" | |- align="center" | ||
|'''Shigella species''' || [[TMP-SMZ]], 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or [[fluoroquinolone]] (e.g., 300 mg ofloxacin, 400 mg norfloxacin, or 500 mg ciprofloxacin b.i.d. 3 3 d); [[nalidixic acid]], 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or [[ceftriaxone]] azithromycin || 3 7–10 d | |'''Shigella species''' || [[TMP-SMZ]], 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or [[fluoroquinolone]] (e.g., 300 mg ofloxacin, 400 mg [[norfloxacin]], or 500 mg [[ciprofloxacin]] b.i.d. 3 3 d); [[nalidixic acid]], 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or [[ceftriaxone]] azithromycin || 3 7–10 d | ||
|- align="center" | |- align="center" | ||
| | | width="20%" |'''Non-typhi species of Salmonella''' || Not recommended routinely, but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, [[TMP-SMZ]] (if susceptible) or [[fluoroquinolone]] as above, b.i.d. 3 5–7 d; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses || 14 d (or longer if relapsing) | ||
|- align="center" | |||
|'''Campylobacter species''' || [[Erythromycin]], 500 mg b.i.d. 3 5 dc || Same (but may require prolonged treatment) | |||
|} | |} | ||
Revision as of 17:45, 29 May 2015
| Pathogen | Immunocompetent patients | Immunocompromised patients |
|---|---|---|
| Shigella species | TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. 3 3 d (if susceptiblea ) or fluoroquinolone (e.g., 300 mg ofloxacin, 400 mg norfloxacin, or 500 mg ciprofloxacin b.i.d. 3 3 d); nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults) 3 5 d [220] or ceftriaxone azithromycin | 3 7–10 d |
| Non-typhi species of Salmonella | Not recommended routinely, but if severe or patient is !6 mo or 150 y old or has prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia, TMP-SMZ (if susceptible) or fluoroquinolone as above, b.i.d. 3 5–7 d; ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses | 14 d (or longer if relapsing) |
| Campylobacter species | Erythromycin, 500 mg b.i.d. 3 5 dc | Same (but may require prolonged treatment) |